■呼吸道合胞病毒(RSV)在婴儿和成人中引起严重的下呼吸道感染(LRTI)。虽然最近估计了德国成年人的临床负担,对经济负担还知之甚少。为了填补这个空白,我们旨在评估德国成人医院和门诊医疗资源利用(HRU)和RSV感染的成本.
■在这次回顾中,全国范围的观察研究,代表,匿名索赔数据(2015-2018年),我们确定了RSV特异性ICD-10-GM编码≥18岁的患者(\'RSV特异性\').为了提高灵敏度,患有未指明的LRTIs(包括未指明的支气管炎,细支气管炎,支气管肺炎,和肺炎)在RSV季节也包括在内,作为可能由RSV引起的病例(\'RSV-可能\')。与RSV相关的HRU(住院天数,ICU和通气治疗,药物分配)和每集估计直接费用。将每次发作和随访期的超额费用与匹配的对照组进行比较。所有结果均按医疗保健部门报告,并按年龄和风险组以及疾病严重程度(ICU入院/通气)进行分层。
■直接住院和门诊平均发作费用分别为3,473欧元和82欧元,分别,对于需要重症监护和/或通气的严重病例,费用要高得多(10,801€)。RSV特异性病例的直接费用高于RSV可能病例(住院患者:6,247€vs.3,450欧元;门诊患者:127欧元vs.82欧元)。此外,RSV患者的费用明显高于对照组,并且随着时间的推移而增加(住院患者:每次5,140欧元vs每年10,093欧元;门诊患者:每季度46欧元vs每年114欧元).
■虽然RSV特异性病例数较低,纳入季节性LRTI病例可能会提高检测RSV病例的敏感性,并允许更好地估计RSV的总费用.
■RSV-LRTI在德国成年人中的经济负担是巨大的,长期持续,尤其是老年人。这突出表明需要有成本效益的预防措施。
UNASSIGNED: Respiratory syncytial virus (RSV) causes severe lower respiratory tract infections (LRTI) in infants and adults. While the clinical burden was recently estimated in adults in Germany, little is known about the economic burden yet. To fill this gap, we aimed to assess hospital and outpatient healthcare resource utilization (HRU) and costs of RSV infections in adults in Germany.
UNASSIGNED: In this retrospective, observational study on nationwide, representative, anonymized claims data (2015-2018), we identified patients ≥18 years with ICD-10-GM-codes specific to RSV (\'RSV-specific\'). To increase sensitivity, patients with unspecified LRTIs (including unspecified bronchitis, bronchiolitis, bronchopneumonia, and pneumonia) during RSV seasons were also included as cases potentially caused by RSV (\'RSV-possible\'). RSV-related HRU (hospital days, ICU and ventilation treatment, drug dispensation) and direct costs were estimated per episode. Excess costs per episode and for follow-up periods were compared to a matched control cohort. All outcomes were reported per healthcare sector and stratified by age and risk groups as well as disease severity (ICU admission/ventilation).
UNASSIGNED: Direct inpatient and outpatient mean episode costs were 3,473€and 82€, respectively, with substantially higher costs for severe cases requiring intensive care and/or ventilation (10,801€). Direct costs for RSV-specific cases were higher than for RSV-possible cases (inpatients: 6,247€vs. 3,450€; outpatients: 127€vs. 82€). Moreover, costs were significantly higher for RSV patients than for controls and increased over time (inpatients: 5,140€per episode vs 10,093€per year; outpatients: 46€per quarter vs 114€per year).
UNASSIGNED: While the number of RSV-specific cases was low, inclusion of seasonal LRTI cases likely increased the sensitivity to detect RSV cases and allowed a better estimation total costs of RSV.
UNASSIGNED: The economic burden of RSV-LRTI in adults in Germany is substantial, persists long-term and is particularly high in the elderly. This highlights the need for cost-effective prevention measures.